An Indirect Treatment Comparison of Cabozantinib Verse Vandetanib in Progressive Medullary Thyroid Cancer (MTC) von Rinciog, C, Myrén, K.J, Aldén, M, Diamantopoulos, A, LeReun, C

Volltext

PMH67 Drug Utilisation Adaptations in Sweden After the Effexor Patent Expiry von Bruce, S, Hjelmgren, J, Löfroth, E, Myrén, K.J

Volltext

PCV26 Real World Add-On and Switch Patterns for Platelet Aggregation Inhibitors von Löfroth, E, Bruce, S, Myrén, K.J

Volltext

PMD69 Treatment of Urinary Tract infections is Common amongst Swedish Patients in Need of Chronic Catheterisation von Bruce, S, Löfroth, E, Knutsson, B, Börstell, T, Myrén, K.J

Volltext

PMD55 Resource Utilisation related to Urinary Tract infections in Swedish Self-Catheterisation Patients von Löfroth, E, Bruce, S, Knutsson, B, Börstell, T, Myrén, K.J

Volltext

PMD54 Resource Utilisation Related to Catheter-associated Urinary Tract infections in Swedish Spinal injury Patients von Bruce, S, Löfroth, E, Knutsson, B, Börstell, T, Myrén, K.J

Volltext

Indirect comparisons of efficacy and weekly factor consumption during continuous prophylaxis with recombinant factor VIII Fc fusion protein and conventional recombinant factor VIII... von Iorio, A., Krishnan, S., Myrén, K.J., Lethagen, S., McCormick, N., Yermakov, S., Karner, P.

Volltext

PCN15 - An Indirect Treatment Comparison of Cabozantinib Verse Vandetanib in Progressive Medullary Thyroid Cancer (MTC) von Rinciog, C., Myrén, K.J., Aldén, M., Diamantopoulos, A., LeReun, C.

Volltext

PCR187 Patient and Physician Satisfaction of Treatment with Eculizumab or Ravulizumab in Paroxysmal Nocturnal Hemoglobinuria: Results from a Real-World Disease-Specific Programme von Füreder, W., Mellor, J., Earl, L., Wang, A., Patel, Y., Myren, K.J., Nagalla, S.

Volltext

PCR123 Assessing the Impact of Relapses on Burden to the Patient and Caregiver in NMOSD von Kleman, M., Tursunova, S., Tibung, J.T., Myren, K.J., Unsworth, M., Castellano, G., Trenholm, E., Grant, N., Le Brocq, L., Fitzmaurice, K.

Volltext

PCR177 Assessing the Impact of Relapses on Patient Outcomes in NMOSD von Kleman, M., Tursunova, S., Tibung, J.T., Myren, K.J., Unsworth, M., Castellano, G., Trenholm, E., Grant, N., Le Brocq, L., Fitzmaurice, K.

Volltext

PRO36 A US COST-MINIMIZATION MODEL COMPARING LIFETIME PER-PATIENT COSTS FOR RAVULIZUMAB AND ECULIZUMAB FOR THE TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME von Wang, Y., Johnston, K., Popoff, E., Myren, K.J., Cheung, A., Faria, C., Tomazos, I.

Volltext

PRO155 COST–UTILITY ANALYSIS OF RAVULIZUMAB COMPARED WITH ECULIZUMAB IN GERMAN ADULT OUTPATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA von OConnell, T., Buessing, M.G., Tu, L., Tomazos, I., Thomas, S.K., Myren, K.J.

Volltext

PRO30 Utility Values Associated with Treatment Attributes for Atypical Hemolytic Uremic Syndrome: A Discrete Choice Experiment in 5 Countries von Williams, K., Daniel, A., Chen, P., Myren, K.J., Anokhina, K., Piglowska, N., Lloyd, A.J., Tomazos, I., Wang, Y.

Volltext

PRO32 PREFERENCE WEIGHTS FOR QUALITY-ADJUSTED LIFE-YEARS ESTIMATION FOR TREATMENTS OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA IN FIVE COUNTRIES von Lloyd, A.J., Gallop, K., Ali, S., Myren, K.J., Sierra, J.R., Anokhina, K., Patriquin, C., Hill, A., Tomazos, I.

Volltext

PSY9 PREFERENCE WEIGHTS FOR QUALITY-ADJUSTED LIFE-YEARS ESTIMATION FOR TREATMENTS OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA IN THE UNITED KINGDOM von Lloyd, A.J., Gallop, K., Ali, S., Myren, K.J., Sierra, J.R., Anokhina, K., Patriquin, C., Hill, A., Tomazos, I.

Volltext